Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TL-925 in allergic conjunctivitis
NCT06153342Phase 2Recruiting
- Sponsor
- Telios Pharma
- Start
- Nov 2023
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in allergic conjunctivitis (AC) comparing TL-925 Arm with Placebo Arm (2 arms). Primary endpoints: Ocular itching and Conjunctival redness. Started Nov 2023; status: recruiting.
02
Drugs
TL-925
03
Conditions
allergic conjunctivitis (AC)
Beyond the preview
Go deeper on NCT06153342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06153342.